
## Erik Mittra

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11308819/publications.pdf Version: 2024-02-01



Ερικ Μιττρλ

#	Article	IF	CITATIONS
1	Landscape Analysis of Phase 2 and 3 Clinical Trials for Targeted Radionuclide Therapy. Journal of Nuclear Medicine, 2021, 62, 1031-1032.	5.0	5
2	Correlation of 18-fluorodeoxyglucose PET/computed tomography parameters and clinical features to predict outcome for diffuse large B-cell lymphoma. Nuclear Medicine Communications, 2021, 42, 792-799.	1.1	2
3	Somatostatin Receptor Imaging and Theranostics: Current Practice and Future Prospects. Journal of Nuclear Medicine, 2021, 62, 1323-1329.	5.0	31
4	Low-count whole-body PET with deep learning in a multicenter and externally validated study. Npj Digital Medicine, 2021, 4, 127.	10.9	34
5	177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2021, 22, 1752-1763.	10.7	195
6	Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2372-2382.	6.4	79
7	Predicting Response to Immunotherapy by Evaluating Tumors, Lymphoid Cell-Rich Organs, and Immune-Related Adverse Events Using FDG-PET/CT. Clinical Nuclear Medicine, 2019, 44, e272-e279.	1.3	80
8	A Feasibility Study of Single-inhalation, Single-energy Xenon-enhanced CT for High-resolution Imaging of Regional Lung Ventilation in Humans. Academic Radiology, 2019, 26, 38-49.	2.5	2
9	Radioactive iodine in differentiated thyroid cancer: a national database perspective. Endocrine-Related Cancer, 2019, 26, 795-802.	3.1	30
10	Update 2018. Clinical Nuclear Medicine, 2018, 43, e439-e452.	1.3	15
11	PD-1 Blockade–induced Inflammatory Arthritis. Radiology, 2018, 289, 616-616.	7.3	7
12	Detection of nociceptive-related metabolic activity in the spinal cord of low back pain patients using <sup>18</sup> F-FDG PET/CT. Scandinavian Journal of Pain, 2017, 15, 53-57.	1.3	7
13	Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors. New England Journal of Medicine, 2017, 376, 125-135.	27.0	2,206
14	Response Assessment Criteria and Their Applications in Lymphoma: Part 2. Journal of Nuclear Medicine, 2017, 58, 13-22.	5.0	33
15	Response Assessment Criteria and Their Applications in Lymphoma: Part 1. Journal of Nuclear Medicine, 2016, 57, 928-935.	5.0	21
16	Bone-Targeted Imaging and Radionuclide Therapy in Prostate Cancer. Journal of Nuclear Medicine, 2016, 57, 19S-24S.	5.0	30
17	Clinically Approved Nanoparticle Imaging Agents. Journal of Nuclear Medicine, 2016, 57, 1833-1837.	5.0	181
18	<sup>68</sup> Ga-DOTA-Bombesin ( <sup>68</sup> Ga-RM2 or <sup>68</sup> Ga-Bombesin) PET versus <sup>68</sup> Ga-PSMA PET: A pilot prospective evaluation in patients with biochemical recurrence of prostate cancer Journal of Clinical Oncology, 2016, 34, 331-331.	1.6	2

Erik Mittra

#	Article	IF	CITATIONS
19	Combined 18F-NaF and 18F-FDG PET/CT in the Evaluation of Sarcoma Patients. Clinical Nuclear Medicine, 2015, 40, 720-724.	1.3	17
20	Semiquantitative Analysis of the Biodistribution of the Combined 18F-NaF and 18F-FDG Administration for PET/CT Imaging. Journal of Nuclear Medicine, 2015, 56, 688-694.	5.0	15
21	Biodistribution of the 18F-FPPRGD2 PET radiopharmaceutical in cancer patients: an atlas of SUV measurements. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1850-1858.	6.4	43
22	Glioblastoma Multiforme Recurrence: An Exploratory Study of18F FPPRGD2PET/CT. Radiology, 2015, 277, 497-506.	7.3	49
23	Safety and tolerability of increasing doses of CB-839, a first-in-class, orally administered small molecule inhibitor of glutaminase, in solid tumors Journal of Clinical Oncology, 2015, 33, 2512-2512.	1.6	45
24	<sup>18</sup> F-FPPRGD2 PET/CT: Pilot Phase Evaluation of Breast Cancer Patients. Radiology, 2014, 273, 549-559.	7.3	47
25	Clinical evaluation of a novel intraoperative handheld gamma camera for sentinel lymph node biopsy. Physica Medica, 2014, 30, 340-345.	0.7	40
26	Pulmonary Ventilation Imaging Based on 4-Dimensional Computed Tomography: Comparison With Pulmonary Function Tests andÂSPECT Ventilation Images. International Journal of Radiation Oncology Biology Physics, 2014, 90, 414-422.	0.8	81
27	A brain tumor molecular imaging strategy using a new triple-modality MRI-photoacoustic-Raman nanoparticle. Proceedings of SPIE, 2013, , .	0.8	2
28	Prediction of trabecular bone qualitative properties using scanning quantitative ultrasound. Acta Astronautica, 2013, 92, 79-88.	3.2	22
29	Pilot Prospective Evaluation of 99mTc-MDP Scintigraphy, 18F NaF PET/CT, 18F FDG PET/CT and Whole-Body MRI for Detection of Skeletal Metastases. Clinical Nuclear Medicine, 2013, 38, e290-e296.	1.3	61
30	Combined 18F-Fluoride and 18F-FDG PET/CT Scanning for Evaluation of Malignancy: Results of an International Multicenter Trial. Journal of Nuclear Medicine, 2013, 54, 176-183.	5.0	52
31	A brain tumor molecular imaging strategy using a new triple-modality MRI-photoacoustic-Raman nanoparticle. Nature Medicine, 2012, 18, 829-834.	30.7	1,029
32	Prospective Evaluation of 99mTc MDP Scintigraphy, 18F NaF PET/CT, and 18F FDG PET/CT for Detection of Skeletal Metastases. Molecular Imaging and Biology, 2012, 14, 252-259.	2.6	135
33	First Experience with Clinical-Grade [18F]FPP(RGD)2: An Automated Multi-step Radiosynthesis for Clinical PET Studies. Molecular Imaging and Biology, 2012, 14, 88-95.	2.6	73
34	Reply: Combined <sup>18</sup> F-FDG and Fluoride Approach in PET/CT Imaging: Is There a Clinical Future?. Journal of Nuclear Medicine, 2010, 51, 166-167.	5.0	4
35	18F-FDG-PET and PET/CT for Evaluating Primary Bone Tumors. PET Clinics, 2010, 5, 327-339.	3.0	2
36	Novel Strategy for a Cocktail 18F-Fluoride and 18F-FDG PET/CT Scan for Evaluation of Malignancy: Results of the Pilot-Phase Study. Journal of Nuclear Medicine, 2009, 50, 501-505.	5.0	105

Erik Mittra

#	Article	IF	CITATIONS
37	Efficacy of 18F-FDG PET/CT in the evaluation of patients with recurrent cervical carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1952-1959.	6.4	80
38	Positron Emission Tomography/Computed Tomography: The Current  Technology and Applications. Radiologic Clinics of North America, 2009, 47, 147-160.	1.8	67
39	Cutaneous Graft-Versus-Host Disease on Tc-99m Leukocyte Scintigraphy. Clinical Nuclear Medicine, 2009, 34, 894-895.	1.3	1
40	Evaluation of trabecular mechanical and microstructural properties in human calcaneal bone of advanced age using mechanical testing, μCT, and DXA. Journal of Biomechanics, 2008, 41, 368-375.	2.1	52
41	Positron Emission Tomography of Bone in Small Animals. , 2008, , 331-346.		Ο
42	A Case of Three Synchronous Primary Tumors Demonstrated by F-18 FDG PET. Clinical Nuclear Medicine, 2007, 32, 666-667.	1.3	5
43	Concurrent metabolic and osseous metastatic disease on a Tc99m-MDP bone scan. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 2150-2150.	6.4	0
44	The effects of embedding material, loading rate and magnitude, and penetration depth in nanoindentation of trabecular bone. Journal of Biomedical Materials Research - Part A, 2006, 79A, 86-93.	4.0	45
45	Interrelationship of trabecular mechanical and microstructural properties in sheep trabecular bone. Journal of Biomechanics, 2005, 38, 1229-1237.	2.1	158
46	Quantity and Quality of Trabecular Bone in the Femur Are Enhanced by a Strongly Anabolic, Noninvasive Mechanical Intervention. Journal of Bone and Mineral Research, 2002, 17, 349-357.	2.8	266